ANIXMEDIUM SIGNALFINANCIAL10-K

ANIX shows a 25% decline in total assets and stockholders' equity alongside reduced R&D spending and improved operating losses, while simplifying its therapeutics program focus.

The company appears to be managing cash burn more effectively with reduced R&D and SG&A expenses leading to improved operating losses, but the significant decline in current assets suggests potential liquidity concerns. The streamlined focus on lira-cel therapy and removal of COVID-19 programs indicates strategic refocusing on core oncology assets.

Comparing 2026-01-12 vs 2025-01-10View on EDGAR →
FINANCIAL ANALYSIS

ANIX experienced a broad contraction with total assets declining 25.5% to $16.1M and current assets falling 25.6% to $15.9M, signaling potential cash management challenges. However, the company reduced both R&D expenses by 20.7% and SG&A by 18.1%, leading to improved operating losses from -$13.8M to -$11.7M. The dramatic 91% reduction in capital expenditures and decreased liabilities suggest aggressive cost management, though the overall asset decline raises questions about the company's financial runway.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+128.6%
$175K→$400K

Receivables surged 128.6% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Capital Expenditure
Cash Flow
-91%
$175K→$16K

Capex reduced 91% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
-25.6%
$21.4M→$15.9M

Current assets declined 25.6% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-25.5%
$21.6M→$16.1M

Total assets contracted 25.5% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
-24.2%
$20.0M→$15.2M

Equity decreased 24.2% — buybacks or losses reducing book value, monitor solvency ratios.

Current Liabilities
Balance Sheet
-21.3%
$2.5M→$2.0M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-21.2%
$2.7M→$2.1M

Liabilities reduced 21.2% — deleveraging improves balance sheet strength and financial flexibility.

R&D Expense
P&L
-20.7%
$6.4M→$5.1M

R&D spending cut 20.7% — could signal cost discipline or concerning reduction in innovation investment.

SG&A Expense
P&L
-18.1%
$6.9M→$5.7M

SG&A reduced 18.1% — improved cost efficiency or headcount reduction improving operating margins.

Operating Income
P&L
+15.4%
-$13.8M→-$11.7M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

LANGUAGE CHANGES
NEW — 2026-01-12
PRIOR — 2025-01-10
ADDED
On January 12, 2026, the registrant had outstanding 33,376,690 shares of common stock, par value $ 0.01 per share, which is the registrant s only class of common stock.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 34 Item 13.
Our therapeutics program consists of the development of liraltagene autoleucel ( lira-cel ), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell ( CAR-T ) technology, initially focused on treating ovarian cancer, that is being developed at our subsidiary, Certainty Therapeutics, Inc.
Our vaccine programs include (i) the development of a vaccine against breast cancer, (ii) the development of a vaccine against ovarian cancer, and (iii) a vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate.
Due to such Company funding, Wistar s equity stake in Certainty was 4.1% as of October 31, 2025.
+7 more — sign up free →
REMOVED
On January 10, 2025, the registrant had outstanding 32,196,862 shares of common stock, par value $ 0.01 per share, which is the registrant s only class of common stock.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Our therapeutics programs include (i) the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell ( CAR-T ) technology, initially focused on treating ovarian cancer, which is being developed at our subsidiary, Certainty Therapeutics, Inc.
( Certainty ), and (ii) until March 2023, the development of anti-viral drug candidates for the treatment of COVID-19.
Our vaccine programs include (i) the development of a vaccine against breast cancer, initially focused on triple negative breast cancer ( TNBC ), the most lethal form of breast cancer, (ii) the development of a vaccine against ovarian cancer, and (iii) a vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines, to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →